Streetbeat News

CVSI

CV Sciences Inc.

https://cvsciences.com/

Employees

71

Industry

All Other Miscellaneous Chemical Product and Preparation Manufacturing

Open

0.03

Mkt cap

6.4M

Volume

96K

High

0.04

P/E Ratio

-1.75

52-wk high

0.10

Low

0.03

Div yield

N/A

52-wk low

0.03

CV Sciences, Inc. has announced a definitive agreement to acquire Extract Labs, a manufacturer and distributor of cannabinoid products. This acquisition aims to enhance CV Sciences' product offerings in the wellness sector.

Portfolio Pulse from

November 21, 2024 | 9:45 pm

CV Sciences, Inc. held its Q3 2024 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

November 14, 2024 | 6:30 pm

CV Sciences, Inc. reported its Q3 2024 financial results, showing a slight decrease in revenue to $3.9 million compared to the previous year and quarter. The company maintained a stable gross margin and launched a new product line, +PlusHLTH™.

Portfolio Pulse from

November 14, 2024 | 2:15 pm

CV Sciences, Inc. will announce its third quarter 2024 financial results on November 14, 2024. The company specializes in hemp extracts and natural ingredients. A conference call with investors is scheduled for the same day.

Portfolio Pulse from

November 08, 2024 | 2:15 pm

On November 1, 2024, several cannabis stocks experienced significant price changes. Notable gainers included Australis Capital, CordovaCann, and Cara Therapeutics, while major losers included Cann Group, Greenlane Holdings, and Canopy Growth.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 8:30 pm

The article reports on the performance of various cannabis stocks on October 31, 2024. Notable gainers include Australis Capital, CordovaCann, and Cara Therapeutics, while significant losers include Cann Group, Greenlane Holdings, and Canopy Growth.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 8:30 pm

The article reports on the performance of various cannabis stocks on October 30, 2024. Notable gainers include Australis Capital, CordovaCann, and Cara Therapeutics, while significant losers include Cann Group, Greenlane Holdings, and Canopy Growth.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 8:30 pm

Microsoft shares rise as the company reports better-than-expected Q1 2025 GAAP EPS and sales.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:05 pm

On October 29, 2024, several cannabis-related stocks experienced significant price movements. Currenc Group (NASDAQ:CURR) and Encompass Health (NYSE:EHC) were among the gainers, while Eastside Distilling (NASDAQ:EAST), 22nd Century Group (NASDAQ:XXII), Cara Therapeutics (NASDAQ:CARA), Greenlane Holdings (NASDAQ:GNLN), and Urban-gro (NASDAQ:UGRO) were among the losers.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 8:30 pm

On October 24, 2024, several cannabis stocks experienced significant price movements. Notably, Leafbuyer Techs saw a 400% increase, while Greenlane Holdings dropped by 32.56%.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 8:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.